Copyright
©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Apr 7, 2014; 20(13): 3391-3400
Published online Apr 7, 2014. doi: 10.3748/wjg.v20.i13.3391
Published online Apr 7, 2014. doi: 10.3748/wjg.v20.i13.3391
Ref. | I | Study design | SVR | Fibrosis progression | Discontinuance |
Roche et al[85] (2008) | 113 | Retrospective study | 38% | Fibrosis stage remained stable (78.5%) in patients with SVR and increased (44%) in non-responders | 24% overall did not complete therapy. 38% required the premature discontinuation of either IFN, RBV, or both agents |
Carrión et al[81] (2007) | 81 | Randomized controlled trial | 48% in early fibrosis and 18% in advanced fibrosis | Fibrosis progression -26% in treated group vs 70% in untreated group | Treatment interruption in 22% and 56% of patients with mild and advanced fibrosis respectively |
Neff et al[86] (2004) | 57 | Retrospective study | 24.5% virus negative at 48 wk | Responders to therapy trended toward improvement in level of fibrosis | Overall discontinuation rate 31.5%. Dose adjustments in 74% |
Oton et al[87] (2006) | 55 | Prospective cohort study | 43.60% | No improvement in fibrosis progression | 29% discontinued due to intolerance |
Samuel et al[83] (2003) | 52 | Randomized controlled trial | 21% | No impact on fibrosis progression | Treatment interruption 43% |
Fernández et al[82] (2006) | 47 | Prospective cohort study | 23% | Significant histological improvement in 23% | Treatment interruption in 21% |
Mukherjee et al[84] (2006) | 39 | Prospective cohort study | 33.30% | Improved or stable fibrosis scores were also demonstrated in 66.7% of non-responder | 43.6% discontinuation rates |
- Citation: Dhanasekaran R, Firpi RJ. Challenges of recurrent hepatitis C in the liver transplant patient. World J Gastroenterol 2014; 20(13): 3391-3400
- URL: https://www.wjgnet.com/1007-9327/full/v20/i13/3391.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i13.3391